Hyderabad News Desk

B-Cell Lymphoma Clinical Trial

DelveInsight’s ‘B-Cell Lymphoma Pipeline Insight 2023‘ report provides comprehensive global coverage of pipeline B-Cell Lymphoma therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the B-Cell Lymphoma pipeline domain.

For B-Cell Lymphoma emerging drugs, the B-Cell Lymphoma pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

To know more about B-Cell Lymphoma offerings @ B-Cell Lymphoma Pipeline Insight

Key Takeaways from the B-Cell Lymphoma Pipeline Report

• DelveInsight’s B-Cell Lymphoma Pipeline analysis depicts a robust space with 160+ active players working to develop 170+ pipeline therapies for B-Cell Lymphoma treatment. 
• The leading B-Cell Lymphoma companies include Oncternal Therapeutics, Inc, ZAI Lab, Pfizer, Xynomic Pharmaceuticals, SystImmune Inc., Autolus Limited, Vincerx Pharma, Ubix Therapeutics, Biomea Fusion Inc, Shanghai Hengrui Pharmaceutical, BeiGene, Hanmi Pharmaceutical, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Merck Sharp & Dohme LLC, Sanofi, InnoCare Pharma, Allogene Therapeutics, Cellular Biomedicine Group Ltd., Genentech, Philogen, Aleta Biotherapeutics, Incyte Corporation,  Fundamenta Therapeutics, Ltd., Juventas Cell Therapy, Shanghai Hengrui Pharmaceutical Co., Ltd., Guangzhou Lupeng Pharmaceutical Company LTD., TG Therapeutics Inc., Roche, 2seventy bio, AstraZeneca, Nektar Therapeutics, ADC Therapeutics, Genor Biopharma, Pacylex Pharmaceuticals, Antengene Corporation, Zhejiang DTRM Biopharma, Shanghai Cell Therapy Group Co., Ltd., Nanjing Legend Biotech Co., and others are evaluating their lead assets to improve the B-Cell Lymphoma treatment landscape.
• Key B-Cell Lymphoma pipeline therapies in various stages of development include Zilovertamab, Odronextamab, PF-07901801, Abexinostat, GNC-038, AUTO3, VIP 924, UBX-303-1, BMF-219, SHR-A1912, Ociperlimab, Poseltinib, TQ-B3525, DPX-Survivac, THOR-707, Orelabrutinib, ALLO 501A, Prizloncabtagene autoleucel, Mosunetuzumab, Bifikafusp alfa, ALETA 001, Parsaclisib, ThisCART19A, CNCT-19, SHR-A1912, LP-168, TG-1801, Zanubrutinib, BGB-11417, BGB 16673,  ME-401, BGB-10188,  Tafasitamab, RG 6026, ALLO-647,  bbT369, Capivasertib, NKTR-255, Loncastuximab tesirine, GB-241, MK-2140, PCLX-001, ATG-008, CC-122, BZ019, LCAR-AIO, and others.
• In May 2023, Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced that it has entered into a worldwide collaboration and license agreement with Cellular Biomedicine Group Inc. (CBMG) to develop, manufacture and commercialize next-generation chimeric antigen receptor (CAR) T-cell therapies for the treatment of B-cell malignancies.
• In May 2023, Genmab A/S announced that the U.S. Food and Drug Administration (FDA) has approved EPKINLY™ (epcoritamab-bysp) as the first and only T-cell engaging bispecific antibody for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS), including DLBCL arising from indolent lymphoma, and high-grade B‑cell lymphoma, after two or more lines of systemic therapy.

Request a sample and discover the recent breakthroughs happening in the B-Cell Lymphoma pipeline landscape @ B-Cell Lymphoma Pipeline Outlook

B-Cell Lymphoma Overview

B-cell lymphoma, a prevalent form of non-Hodgkin lymphoma, originates in B-cells. It represents approximately 85% of all lymphoma cases in the United States. Common lymphoma symptoms encompass painless enlargement of lymph nodes, fever, night sweats, and weight loss. Among B-cell lymphomas, Diffuse large B-cell lymphoma (DLBCL) is the most frequent subtype. The current World Health Organization (WHO) classification system employs morphological, immunophenotypic, genotypic, and clinical criteria to categorize lymphoid neoplasms into five primary groups: precursor B-cell neoplasms, peripheral B-cell neoplasms, precursor T-cell neoplasms, peripheral T-cell neoplasms, and Hodgkin lymphoma. Despite its B-cell origin, Hodgkin lymphoma possesses distinct pathological characteristics and is managed as a distinct entity. The treatment for this condition encompasses a range of approaches, including chemotherapy, steroid administration, radiation therapy, and marrow transplantation. In pediatric cases, approximately 95% of children achieve complete remission, with 75-85% being successfully cured through chemotherapy. On the other hand, the cure rate for adults is notably lower, standing at 35-40%. It’s important to note that the introduction of BCR-ABL kinase inhibitors, when combined with conventional chemotherapy, has substantially enhanced the prognosis in children with t(9;22)-positive ALLs, leading to significantly improved outcomes.

Find out more about B-Cell Lymphoma medication @ B-Cell Lymphoma Clinical Trial 

B-Cell Lymphoma Treatment Analysis: Drug Profile

Odronextamab: ZAI Lab

Odronextamab, an IgG4-based bispecific antibody of human origin, simultaneously targets CD3, a T-cell antigen involved in the T-cell receptor complex, and CD20, a B-cell surface antigen found on normal B cells as well as various B cell lineage malignancies. Currently, a Phase 2 study with the potential to be pivotal is underway to evaluate the efficacy of odronextamab in treating B-cell non-Hodgkin lymphoma (B-NHL), which includes follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), and marginal zone lymphoma (MZL). In April 2020, Zai Lab acquired the exclusive rights for the development and commercialization of odronextamab in greater China from Regeneron Pharmaceuticals.

NKTR-255: Nektar Therapeutics

NKTR-255 is a biologic designed to target the IL-15 pathway, with the goal of stimulating both the innate and adaptive immune systems. By effectively engaging the IL-15 receptor complex, NKTR-255 aims to bolster functional NK cell populations and promote the development of enduring immunological memory. These effects may result in a prolonged and robust anti-tumor immune response. Preclinical research suggests that NKTR-255 has the potential to complement antibody-dependent cellular cytotoxicity agents and enhance CAR-T therapies. Currently, the drug is undergoing Phase II/III clinical trials for the treatment of Relapsed/Refractory Large B-cell Lymphoma.

Key B-Cell Lymphoma Therapies and Companies

• Odronextamab: ZAI Lab
• NKTR-255: Nektar Therapeutics
• Zilovertamab: Oncternal Therapeutics, Inc
• PF-07901801: Pfizer
• Abexinostat: Xynomic Pharmaceuticals
• LP-168: Guangzhou Lupeng Pharmaceutical Company LTD.
• GNC-038: SystImmune Inc.
• AUTO3: Autolus Limited
• TG-1801: TG Therapeutics, Inc.

Learn more about the novel and emerging B-Cell Lymphoma pipeline therapies @ B-Cell Lymphoma Pipeline Outlook

B-Cell Lymphoma Therapeutics Assessment

• By Product Type
• Monotherapy
• Combination Therapy
• By Stage
• Discovery
• Pre-Clinical
• Phase I
• Phase II
• Phase III
• Pre-registration
• By Route of Administration

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
• By Molecule Type
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Scope of the B-Cell Lymphoma Pipeline Report 

• Coverage: Global 
• Key B-Cell Lymphoma Companies: Oncternal Therapeutics, Inc, ZAI Lab, Pfizer, Xynomic Pharmaceuticals, SystImmune Inc., Autolus Limited, Vincerx Pharma, Ubix Therapeutics, Biomea Fusion Inc, Shanghai Hengrui Pharmaceutical, BeiGene, Hanmi Pharmaceutical, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Merck Sharp & Dohme LLC, Sanofi, InnoCare Pharma, Allogene Therapeutics, Cellular Biomedicine Group Ltd., Genentech, Philogen, Aleta Biotherapeutics, Incyte Corporation,  Fundamenta Therapeutics, Ltd., Juventas Cell Therapy, Shanghai Hengrui Pharmaceutical Co., Ltd., Guangzhou Lupeng Pharmaceutical Company LTD., TG Therapeutics Inc., Roche, 2seventy bio, AstraZeneca, Nektar Therapeutics, ADC Therapeutics, Genor Biopharma, Pacylex Pharmaceuticals, Antengene Corporation, Zhejiang DTRM Biopharma, Shanghai Cell Therapy Group Co., Ltd., Nanjing Legend Biotech Co., and others.
• Key B-Cell Lymphoma Pipeline Therapies: Zilovertamab, Odronextamab, PF-07901801, Abexinostat, GNC-038, AUTO3, VIP 924, UBX-303-1, BMF-219, SHR-A1912, Ociperlimab, Poseltinib, TQ-B3525, DPX-Survivac, THOR-707, Orelabrutinib, ALLO 501A, Prizloncabtagene autoleucel, Mosunetuzumab, Bifikafusp alfa, ALETA 001, Parsaclisib, ThisCART19A, CNCT-19, SHR-A1912, LP-168, TG-1801, Zanubrutinib, BGB-11417, BGB 16673,  ME-401, BGB-10188,  Tafasitamab, RG 6026, ALLO-647,  bbT369, Capivasertib, NKTR-255, Loncastuximab tesirine, GB-241, MK-2140, PCLX-001, ATG-008, CC-122, BZ019, LCAR-AIO, and others.

Dive deep into rich insights for drugs used for B-Cell Lymphoma treatment; visit @ B-Cell Lymphoma Drugs

Table of Contents

1. Introduction

2. Executive Summary

3. B-Cell Lymphoma Pipeline: Overview

4. Analytical Perspective In-depth Commercial Assessment

5. B-Cell Lymphoma Pipeline Therapeutics

6. B-Cell Lymphoma Pipeline: Late-Stage Products (Phase III)

7. B-Cell Lymphoma Pipeline: Late-Stage Products (Phase III)

8. B-Cell Lymphoma Pipeline: Mid-Stage Products (Phase II)

9. B-Cell Lymphoma Pipeline: Early Stage Products (Phase  I)

10. Therapeutic Assessment

11. Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Key Companies

14. Key Products

15. Unmet Needs

16. Market Drivers and Barriers

17. Future Perspectives and Conclusion

18. Analyst Views

19. Appendix

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.  Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting